Polaryx Therapeutics, Inc.PLYX
Price (close)
$2.14
Market cap
$95.6M
P/E
—
Revenue (FY)
—
Net income
-$9.0M
Dividend yield
—
1-year total return
—
Net margin
—
Revenue growth
—
Debt / equity
—
What Polaryx Therapeutics, Inc. does.
to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Our therapeutic philosophy
is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic
diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy,
Revenue and profit, by fiscal year.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net income | — | -$30.4M | -$9.0M |
More on PLYX.
- Polaryx Therapeutics, Inc. summary
- Polaryx Therapeutics, Inc. financial statements
- Polaryx Therapeutics, Inc. key metrics
- Polaryx Therapeutics, Inc. health scores and style box
- Polaryx Therapeutics, Inc. earnings
- Polaryx Therapeutics, Inc. dividends
- Polaryx Therapeutics, Inc. valuation
- Polaryx Therapeutics, Inc. ownership and insiders
- Polaryx Therapeutics, Inc. peers
Figures from Polaryx Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.